Exploration Experiments in Wavelet Video Coding

This document defines the Exploration Experiments (EE) to be conducted by the VidWav AHG till the Bangkok meeting. The common software platform was decided to be used by all the participants in the EEs. It is already available on the CVS server provided by RWTH. During the Poznan meeting, tools had been identified as potentially useful, and the associated experiment was not completes for this meeting. These previous EE are being extended till next meeting

Проектирование технологического процесса изготовления детали «Щит подшипника в сборе» и оснастки

Объектом исследования является деталь "Щит подшипниковый", технологический процесс его изготовления и приспособление. Цель работы - разработка наиболее эффективного технологического процесса. В результате исследования получены более оптимальные экономические и технологические показатели.The object of study is the detail of the "Shield bearing", the technological process of its manufacture and adaptation. Goal - to develop the most efficient process. The study obtained better economic and technological performance

Учет и анализ оплаты труда и расчетов с персоналом в ГАУ «Юргинском психоневрологическом интернате»

Объектом исследования в бакалаврской работе является ГАУ "Юргинский психоневрологический интернат". Предмет исследования – учет и анализ расчетов с персоналом по оплате труда в ГАУ "Юргинский психоневрологический интернат". Цель работы - разработка рекомендации по совершенствованию учета расчетов по оплате труда в ГАУ "Юргинский психоневрологический интернат".The object of research in the work is GAU "Yurginsky neuropsychiatric boarding school". The subject of the research is the accounting and analysis of settlements with staff on remuneration in GAU "Yurginsky neuropsychiatric boarding school". The purpose of the work is to develop a recommendation for improving the accounting of payments for wages in GAU "Yurginsky neuropsychiatric boarding school"

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)

Jensen-Shannon divergence for visual quality assessment

This paper focuses on some theoretical properties of the Jensen-Shannon divergence (JSD) that well match human visual system (HVS) features. In particular, it is firstly shown that JSD between the probability density function (pdf) of the reference (original) image and the test (distorted) one can be reformulated as a mathematical expansion, independently of the image subject and the distortion kind. Such expansion contains a component of the well-known structural similarity measure (SSIM), some powers of the Weber's law, and an additional component tied to the skewness of the involved pdfs. This theoretical link with some HVS-based quantities is further stressed by some experimental results showing that JSD has a trend similar to other popular quality assessment measures like SSIM, VIF, and MSE on frequent degradation kinds like JPEG, Additive Gaussian Noise, Gaussian Blur, and JPEG2K. Experimental tests on several images from LIVE database show that the proposed approach can be a valid theoretical and objective support for modeling HVS behavior. © 2013 Springer-Verlag London